Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Puerto Rico, Costa Rica, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. The company was founded in 1970 and is headquartered in Plano, Texas.
EP Market Dominance | Integer Holdings poised for growth in Electrophysiology sector, particularly with involvement in pulse field ablation technology development |
Financial Resilience | Despite recent revenue slowdown, analysts remain confident in Integer's ability to meet full-year outlook and long-term financial goals |
Margin Expansion | Company progressing towards pre-COVID profit levels, with potential to surpass them through operational efficiency and strategic initiatives |
Analyst Perspectives | KeyBanc Capital Markets and KeyCorp maintain Overweight rating with $139 price target, reflecting positive outlook on Integer's market position |
Metrics to compare | ITGR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipITGRPeersSector | |
---|---|---|---|---|
P/E Ratio | 44.5x | −11.1x | −0.5x | |
PEG Ratio | −1.84 | −0.30 | 0.00 | |
Price/Book | 2.2x | 2.5x | 2.6x | |
Price / LTM Sales | 2.1x | 3.7x | 3.3x | |
Upside (Analyst Target) | 31.4% | 52.1% | 45.4% | |
Fair Value Upside | Unlock | 7.8% | 7.7% | Unlock |